Skip to content

Research on the Development and Validation of Personalized Exercise Prescriptions for Breast Cancer Patients Based on Large Language Models

Research on the Development and Validation of Personalized Exercise Prescriptions for Breast Cancer Patients Based on Large Language Models

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07619781
Enrollment
220
Registered
2026-06-02
Start date
2025-10-01
Completion date
2027-07-01
Last updated
2026-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

The goal of this observational study is to develop and evaluate a large language model (LLM)-based decision support system for exercise prescription in breast cancer patients, aiming to provide personalized decision-making support for postoperative breast cancer rehabilitation. The main questions it aims to answer are: How accurate, personalized, and safe are the exercise prescriptions generated by the fine-tuned LLM? How does the model's performance compare with other mainstream or non-fine-tuned models across different stages and subtypes of breast cancer? Participants are postoperative breast cancer rehabilitation patients treated at Sun Yat-sen Memorial Hospital of Sun Yat-sen University. They will have demographic, tumor, treatment, and physical fitness data collected; receive personalized exercise prescriptions automatically generated by the LLM-based system; and provide subjective evaluations on the feasibility and executability of the prescriptions.

Interventions

None listed

Sponsors

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Adult patients aged 18-75 years with early-stage breast cancer who have undergone surgical treatment, such as mastectomy or breast-conserving surgery. * ECOG performance status of 0-1, with adequate physical condition to participate in rehabilitation assessment and exercise prescription activities. * Availability of essential clinical data, including demographic characteristics, tumor stage and subtype, treatment history, and baseline physical fitness assessment. * Able to communicate effectively, maintain stable follow-up contact, and voluntarily participate in evaluation and feedback on exercise prescriptions.

Exclusion criteria

* Presence of severe postoperative complications or comorbidities (e.g., uncontrolled cardiac or pulmonary disease) that may interfere with participation in rehabilitation or pose a safety risk. * Significant physical or mobility impairments preventing the performance of prescribed exercises. * Severe psychiatric illness or cognitive dysfunction that hinders cooperation with assessments or follow-up. * Incomplete or missing key clinical data, making evaluation or follow-up impossible. * Any other condition deemed inappropriate for participation by the investigators.

Design outcomes

Primary

MeasureTime frame
Average 5-point Likert scores across five expert-defined dimensions-individualization, comprehensiveness, scientific rationality, safety, and executability-are used to compare the performance of fine-tuned models with that of mid-level physicians.From enrollment to completion of prescription evaluation at 1 week

Secondary

MeasureTime frameDescription
Evaluation Form for Consistency Between Model Diagnostic Logic and Medical ConsensusFrom enrollment to completion of prescription evaluation at 1 weekMeasurement Method/Unit: A panel of expert reviewers (at least 3 senior physicians) conducts a blinded assessment of the model's diagnostic reasoning pathways in test cases using a dedicated evaluation form. The outcome is expressed as the mean score (points). Rating Scale: 5-point Likert scale (1=Highly Unsound, 5=Highly Sound) Interpretation of Scores: A higher score indicates better consistency of the model's diagnostic logic with established medical consensus.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 3, 2026